Mode
Text Size
Log in / Sign up

Inflammatory bowel disease is associated with increased risk of MACE and all-cause mortalityInflammatory bowel disease linked to higher heart attack risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that IBD is associated with higher risk of MACE, all-cause mortality, and major bleeding after myocardial infarction.

This systematic review and meta-analysis synthesized data from 9 retrospective cohort studies involving 9.45 million patients to evaluate the impact of inflammatory bowel disease (IBD) on cardiovascular outcomes following an index myocardial infarction. The analysis indicates that IBD is associated with a significantly increased risk of major adverse cardiovascular events (MACE; HR 1.31, 95% CI 1.07-1.59), all-cause mortality (HR 1.25, 95% CI 1.12-1.39), and recurrent myocardial infarction (HR 1.22, 95% CI 1.08-1.39).

Additionally, the meta-analysis found that IBD patients had increased odds of major bleeding (OR 1.38, 95% CI 1.13-1.70) and transfusion (OR 1.41, 95% CI 1.35-1.47). Conversely, lower odds were observed for heart failure (OR 0.81, 95% CI 0.74-0.89), though the authors caution that this may reflect surveillance bias rather than a protective effect. No significant difference was found regarding stroke.

The study is limited by its reliance on observational data and potential residual confounding. These findings suggest that patients with IBD may require specialized cardiovascular risk stratification and management strategies for bleeding risks. Because these are observational associations, the results do not imply causality.

How this fits prior evidence

This meta-analysis addresses a gap in understanding how inflammatory bowel disease affects outcomes following myocardial infarction. While previous evidence has explored non-pharmacological interventions to reduce depressive symptoms in patients with IBD, this study focuses on the specific cardiovascular risks and mortality associated with the condition. It provides a broader clinical picture of the systemic complications faced by patients with IBD beyond psychological health.

Living with inflammatory bowel disease (IBD) can put extra strain on your body, especially when it comes to heart health. New data from a large review of millions of patients shows that people with IBD face a much higher risk of serious heart problems after having a heart attack.

The study looked at nearly 9.5 million people. It found that those with IBD were more likely to experience major cardiovascular events, repeat heart attacks, and death compared to people without the condition. The data also showed these patients faced a higher risk of major bleeding and needing blood transfusions.

While the results show a clear link between IBD and heart risks, it is important to remember that this was an observational study. This means researchers can see a connection, but they cannot prove that IBD directly causes these specific heart issues. Because the data comes from past records, there are also limitations regarding how much other factors might have influenced the results.

What this means for you:
People with inflammatory bowel disease face higher risks of heart complications and bleeding after a heart attack.

Common questions

Does having inflammatory bowel disease increase the risk of another heart attack?

Yes. The data shows that patients with inflammatory bowel disease (IBD) have a significantly higher risk of recurrent myocardial infarction, which is the medical term for a repeat heart attack. Specifically, the study found an increased risk for these events compared to people without IBD.

Are there other heart-related risks for people with IBD?

Yes, the study found that people with IBD have a significantly higher risk of major cardiovascular events and all-cause mortality. While the data did not show a significant increase in stroke risk, it did show lower odds for heart failure.

Is there an increased risk of bleeding for these patients?

Yes, the study found that people with inflammatory bowel disease have higher odds of experiencing major bleeding and requiring a blood transfusion. These findings suggest that doctors may need to pay extra attention to managing bleeding risks in these patients.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic systemic inflammatory disorder associated with elevated cardiovascular risk. While prior studies have linked IBD to increased risk of myocardial infarction (MI), post-MI outcomes in this population remain poorly characterized. We aimed to evaluate post-MI outcomes in patients with IBD compared with non-IBD controls. METHODS: A systematic review and meta-analysis was conducted following PRISMA guidelines. Five databases were searched from inception to July 2025. We included observational studies comparing post-MI outcomes in adults with and without IBD. Random-effects meta-analyses were performed using hazard ratios (HRs) and odds ratios (ORs) with 95% CIs. Heterogeneity was assessed using the I2 statistic. RESULTS: Nine retrospective cohort studies encompassing 9.45 million patients were included. IBD was associated with significantly increased risk of MACE (HR: 1.31, 95% CI: 1.07-1.59), all-cause mortality (HR: 1.25, 95% CI: 1.12-1.39), and recurrent MI (HR: 1.22, 95% CI: 1.08-1.39) following index myocardial infarction compared with non-IBD patients. Pooled ORs showed increased odds of major bleeding (OR: 1.38, 95% CI: 1.13-1.70) and transfusion (OR: 1.41, 95% CI: 1.35-1.47), but lower odds of heart failure (OR: 0.81, 95% CI: 0.74-0.89) and no significantly increased odds of stroke. CONCLUSIONS: Patients with IBD have statistically significantly higher risks of MACE, all-cause mortality, recurrent MI, blood transfusions, and major bleeding compared with the non-IBD population. These findings emphasize the potential role for tailored cardiovascular risk stratification, bleeding risk mitigation, and longitudinal management strategies in patients with IBD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.